← MYRIAD GENETICS INC (MYGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MYRIAD GENETICS INC (MYGN)
In Vitro & In Vivo Diagnostic Substances · market cap $391M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Active comparator: Niraparib | Phase 3 | Ovarian Neoplasms |
| Oral rucaparib | Phase 2 | Ovarian Cancer |
Price & technical context
3-month
-28.2%
6-month
-4.2%
12-month
-40.5%
52-wk range
$2.86–$8.18
vs 50-day MA
+16.0%
vs 200-day MA
-9.8%
Realized vol
90.0%
Max drawdown
-90.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MYGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.